Back to search results

129Xe MRI Cardiopulmonary Study for Lung Conditions

This study is looking at how a special type of MRI, using Hyperpolarized Xe129 (xenon gas), can help us understand lung conditions better. Researchers want to characterize three specific markers related to how xenon interacts with red blood cells in your lungs. You might be eligible if you are an adult with conditions like Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, or Polycythemia, or if you are a healthy volunteer. The study will measure changes in these markers after interventions like blood transfusions, apheresis (a procedure to remove blood components), or oxygen administration. The goal is to see how these markers change and what that tells us about your lung health.

Study design
This is an interventional study planning to enroll 125 participants, including healthy volunteers and those with specific lung conditions.
What's involved
Participants will receive Hyperpolarized Xe129 gas and may also receive oxygen. Measurements will be taken at baseline, and then at various times up to 5 days after transfusion/apheresis or 3-6 months post-treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in markers up to 5 days after transfusion/apheresis or 3-6 months post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06038630

129Xe MRI Cardiopulmonary

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
Bastiaan Driehuys
~125 participants
Updated 2026-02-04 on ClinicalTrials.gov
What's tested:Hyperpolarized Xe129Oxygen Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis
Measured over Up to 5 days pre/post transfusion or apheresis
+2 more outcomes measured

Conditions

Interstitial Lung Disease
Chronic Thromboembolic Pulmonary Hypertension
Acute Pulmonary Embolism
Anemia
Polycythemia
Dyspnea

Explore related trials

Acute Pulmonary EmbolismAnemiaChronic Thromboembolic Pulmonary HypertensionDyspneaInterstitial Lung DiseasePolycythemia

NCT06038630

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke University Medical Center

    Durham, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joseph Mammarappallil, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Bastiaan Driehuys, PhD
[email protected]
919-684-7786
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea
Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans
Patients presenting with acute PE 24-48hrs post-admission
Willing to return after 3-6 months of anti-coagulation therapy
Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation
Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans

What this trial measures

  • Change in RBC to Membrane Ratio Pre and Post Transfusion or ApheresisUp to 5 days pre/post transfusion or apheresis

    The investigators will validate the Hb (hemoglobin) correction model in anemia patients pre/post transfusion and blood donors pre/post apheresis.

  • Change in RBC (red blood cell) Chemical Shift After Oxygen AdministrationBaseline, 1 day

    To test the effects of oxygen on 129Xe MRI/MRS in healthy subjects, those with ILD, those with dyspnea, and patients with chronic thromboembolic pulmonary hypertension (CTEPH).

  • Change in RBC Oscillation Amplitude Post TherapyBaseline, 3-6 months post-treatment

    Patients with chronic PE are treated surgically and those with acute PE are treated with anticoagulation therapy.